Drug class
Long-acting C-type natriuretic peptide (CNP) analogue; growth-plate signalling modulator
Mechanism of action
Releases active CNP that binds natriuretic peptide receptor B (NPR-B/guanylyl cyclase B) in growth-plate chondrocytes, increasing intracellular cGMP and attenuating FGFR3-mediated signalling that suppresses endochondral bone growth.
General use cases
- To increase linear growth in paediatric patients aged 2 years and older with achondroplasia and open epiphyses under the US FDA YUVIWEL indication (approved 27 February 2026); accelerated approval is based on improved annualised growth velocity
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
